Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy‐naive metastatic castration‐resistant prostate cancer
The Prostate2017Vol. 77(13), pp. 1373–1380
Citations Over TimeTop 13% of 2017 papers
Baijun Dong, Liancheng Fan, Yanqing Wang, Chenfei Chi, Xiaowei Ma, Rui Wang, Wen Cai, Xiaoguang Shao, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Zhixiang Xin, Jianian Hu, Shaowei Xie, Xiaonan Kang, Lixin Zhou, Wei Xue
Abstract
We hypothesized that AA might not significantly lead to progression of NED of mCRPC in general. Furthermore, we found there was heterogeneity in changes of NED markers in different mCRPC patients during AA treatment. Serial CgA and NSE evaluation might help clinicians guide clinical treatment of mCRPC patients.
Related Papers
- → Neuroendocrine differentiation and prognosis in breast adenocarcinoma(2002)170 cited
- → Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma(2014)47 cited
- Neuroendocrine differentiation in primary Merkel cell carcinoma--possible prognostic significance.(2005)
- → Abiraterone acetate to treat metastatic castration-resistantprostate cancer in combination with prednisone(2019)3 cited
- → The effect of neuroendocrine differentiation on the survival of patients diagnosed with pancreatic ductal adenocarcinoma(2020)